Merck shares rise after beating rivals' lung cancer results
Apr 16, 2018 10:12 a.m. ET
>Monday morning for a cancer drug combination including its drugs Opdivo and Yervoy, finding that the combination improved progression-free survival with patients in a particular subgroup who had a high tumor mutational burden. Progression-free survival, which looks at how long it takes before a patient's cancer worsens, is one measure of a cancer therapy's success but is considered less important than overall survival, which the Merck trial measured.
>The odds of a patient recovering faster with the Merck treatment was 0.49, referring specifically to overall survival, while the odds for a patient on the Bristol-Myers treatment was 0.58, referring specifically to progression-free survival.
>>774
専門的なことはわかりませんが、市場は以下のことで優劣を決めての株価の推移のようです。
Merck shares rise after beating rivals' lung cancer results
Apr 16, 2018 10:12 a.m. ET
>Monday morning for a cancer drug combination including its drugs Opdivo and Yervoy, finding that the combination improved progression-free survival with patients in a particular subgroup who had a high tumor mutational burden. Progression-free survival, which looks at how long it takes before a patient's cancer worsens, is one measure of a cancer therapy's success but is considered less important than overall survival, which the Merck trial measured.
>The odds of a patient recovering faster with the Merck treatment was 0.49, referring specifically to overall survival, while the odds for a patient on the Bristol-Myers treatment was 0.58, referring specifically to progression-free survival.
でも、それらを踏まえてそれぞれの株価は今日までに織り込まれていていいところまで行っているのかもしれません。。。
小野のＡＤＲも８．４１ドル（約２７００円）から売り込む向きもなく８．５１ドル（－１．７１％）まで買いがありましたから。。。。
（ちょっと夜更かしが過ぎましたのでもう寝ます。。。）